{"name":"ARYx Therapeutics","slug":"aryx-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ATI-2042","genericName":"ATI-2042","slug":"ati-2042","indication":"Other","status":"phase_2"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ATI-5923","genericName":"ATI-5923","slug":"ati-5923","indication":"Cognitive impairment associated with schizophrenia","status":"phase_2"}]}],"pipeline":[{"name":"ATI-2042","genericName":"ATI-2042","slug":"ati-2042","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ATI-5923","genericName":"ATI-5923","slug":"ati-5923","phase":"phase_2","mechanism":"ATI-5923 is a selective inhibitor of phosphodiesterase 9 (PDE9) that increases cyclic GMP signaling in the central nervous system.","indications":["Cognitive impairment associated with schizophrenia","Alzheimer's disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNUGxuS3BGNWpUbERPYWhnQ3BnbE50OFdlT2RvaXFrOW1fZHNnb2xmRUtUS1VoNHRNRVFDbkNzNFFLZzVJMDdNVXJLNzFRT2VrY21FTEV6YU1RdGFWT2YtdVMyT0JpWWNoWlE2dUdCWGNwcXNqMm5aX2U1c2J1ZHJyazFkTndNX2NPaGJGa2huRG15bF9HSEpVRXRVSUJuQWs?oc=5","date":"2024-04-25","type":"pipeline","source":"Life Science Leader","summary":"Reviva Pharma's Novel Funding Approach In Schizophrenia - Life Science Leader","headline":"Reviva Pharma's Novel Funding Approach In Schizophrenia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE41ZEJhc2tDano2VmhGSmtoRHlRSUp3bE5lZnkwcFFJZVdnMWpVZlNaT2M3TzNmVVJSSm03UmM0VDBHSE5MM2dwSUdwT3M1bXlWOHJ4TEVR?oc=5","date":"2018-06-07","type":"pipeline","source":"nature.com","summary":"People - nature.com","headline":"People","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFA5eVlKSHhPbnZwN3lUS0JfSmtBSGR5V01TWHZHM0U1T0ptcVQ3MmgyakI0TDFJX1R4S2xpYjRvaWp4bUJHVDI1NjdYNlJmR1Jta3RiRzVHVnhXVkNpUnE4?oc=5","date":"2018-05-03","type":"pipeline","source":"NEJM","summary":"Peripheral Mechanisms in Irritable Bowel Syndrome - NEJM","headline":"Peripheral Mechanisms in Irritable Bowel Syndrome","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE5TYlFjOWRzVkFhODdobVg0SzRKRUpZZlY0X2VrX1Fka2VKQUFSY1lqSnFQMUhvTXg2SmJEN3BtdlZmV2gyUW5vS0oyNEw1dkNjWDRCbThtY0s?oc=5","date":"2017-09-02","type":"pipeline","source":"TradingView","summary":"ARYX Stock Price and Chart — OTC:ARYX - TradingView","headline":"ARYX Stock Price and Chart — OTC:ARYX","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE9jQS1VcFU4SGk0eHRjbjRpcTBKNHpLRnQwbjVHOGZRdnZtTFhjOUdzd2NPX1hMOWhtTkxkZTVReGxqYTEyMGFvTWFXQTlpWWZJdWc?oc=5","date":"2017-05-19","type":"pipeline","source":"Yahoo Finance UK","summary":"ARYx Therapeutics, Inc. (ARYX) stock price, news, quote and history - Yahoo Finance UK","headline":"ARYx Therapeutics, Inc. (ARYX) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxQS1Z4ZXgyVDh1OUFzdUF0VThydUNqS1VOR1N4US0zd3E5T1BZUkZqQW4tOUY0UXIzQzZKN3NGUFFpc1dCNE80SlMyZ1E5cnBocDUyODBUVGxsOUFZQ0hHS2YzN1JaVW1heWhpVThwQVRiNDZYT01ZSE5Xa2FtN29GeUUzaHlKVVBtN0ZDNDRqeFpSaTh4ZGgySFIxd2ZTcFZkU1lQRWEtWFkyN0g0NlFITUtzUTd3MUNGdlVVeFVNaG1XX3NEQk1sYlA5ZFQ3enNSRjZV?oc=5","date":"2015-05-01","type":"pipeline","source":"PR Newswire","summary":"Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments - PR Newswire","headline":"Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQWVItTjVYa2dBWVVmTmY1NDM0SHNxdFF3M1YxNEVwX2pkZWMyYU1sVGdBclozVWtPbXlpTlV5VFZiWGdFc1BGT216M29ZSzdRTms3ZlNYdU9fcXVuYlVEd042SEppaG9wd2NXY3FTdGtpLUlWOGN0U1NIUDhYeURnMGdkckVqQTExRlVxVGl6djhMZTVkSmw4?oc=5","date":"2013-01-10","type":"pipeline","source":"Silicon Republic","summary":"The life scientist – an interview with Peter Milner - Silicon Republic","headline":"The life scientist – an interview with Peter Milner","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNRGxIUUhQM1NHd0ZZbFhWM3V4dkNMZUVRc3RObkF2eTFHdEJoMHEzcXozUVJocWFqSVI5Y3ZYMkpvckYtOEhydFFQMVpQMWlYRTc0R0J2cVZFZVl5RHp1Q2Z3c1FpbS1xeFg3RWktU3lZNnd4UkpUbmhDZi1PVU1DOThCdjZJWnF4aFlHYXllMmt6WXI3X0hOcHFqTXNBeVVUVU5qZXNuQU1TdTdmOXpFaUFpNGtjZw?oc=5","date":"2012-11-13","type":"pipeline","source":"Mayo Clinic News Network","summary":"Mayo Clinic: Irritable Bowel Syndrome Definitely Isn’t ‘All in the Head’ - Mayo Clinic News Network","headline":"Mayo Clinic: Irritable Bowel Syndrome Definitely Isn’t ‘All in the Head’","sentiment":"neutral"},{"date":"2011-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2011-03-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2011-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2011-02-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2011-02-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2010-12-21","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2010-12-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":null,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":null,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}